Thomas Daniel Aicher

USPTO Granted Patents = 53 (Patent Applications = 7)

CIPO Patents = 2

EPO Patents = 16 (Patent Applications = 16)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 222(Granted Patents)

Forward Citations (Not Self Cited) = 75(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Superior, CO (US) (2007 - 2015)
Boulder, CO (US) (2015 - 2016)
Ann Arbor, MI (US) (2014 - 2021)

Company Filing History:

Eli Lilly and Company

patents

4. 8 out of 2,405

Merck Sharp + Dohme Corp.

patents

5. 1 out of 3,370

University of Michigan

patents

where one patent can have more than one assignee

Years Active: 2007-2021

Loading Chart...

53 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11059796 - Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2021-07-13),

2. 10745364 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2020-08-18),

3. 10611740 - Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2020-04-07),

4. 10556898 - Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease (2020-02-11),

5. 10532088 - Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods (2020-01-14),

6. 10442798 - Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-10-15),

7. 10421751 - Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-09-24),

8. 10392350 - N-substituted pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof (2019-08-27),

9. 10377768 - Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-08-13),

10. 10364237 - Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-07-30),

11. 10221146 - Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease (2019-03-05),

12. 10208061 - Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease (2019-02-19),

13. 10189777 - Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease (2019-01-29),

14. 10112935 - Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease (2018-10-30),

15. 10017482 - Mitotic kinesin inhibitors and methods of use thereof (2018-07-10),

Title: The Innovative Journey of Thomas Daniel Aicher

Introduction: Thomas Daniel Aicher, a pioneering inventor based in Ann Arbor, MI, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Thomas Daniel Aicher's latest patents include advancements in artificial intelligence algorithms for autonomous vehicles and cutting-edge medical devices for remote patient monitoring.

Career Highlights: With a career spanning over two decades, Thomas Daniel Aicher has established himself as a leading figure in the tech industry, holding multiple patents in various sectors such as robotics, healthcare, and renewable energy.

Collaborations: Throughout his career, Thomas Daniel Aicher has collaborated with top research institutions, leading companies, and innovative startups to bring his ideas to life and push the boundaries of technological advancements.

Conclusion: Thomas Daniel Aicher's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a visionary inventor shaping the future of technology.

This text is generated by artificial intelligence and may not be accurate.